Workshop 12
Viral vectors and gene therapy

Programme

• 13:30 – 13:45 12 Min. 3 Min.

  • Abstract Talk
  • O 067

  A novel recombinant HBV based selection system allows for a systematic genomic knock-out screening and the identification of host factors involved in HBV infection

  • Bo-Hung Liao (Munich / DE)

   Viral vectors and gene therapy
• 13:45 – 14:00 12 Min. 3 Min.

  • Abstract Talk
  • O 068

  Influenza A virus defective interfering particles as antiviral agents

  • Dr. Sascha Young Kupke (Magdeburg / DE)

   Antiviral therapy and resistance, Viral vectors and gene therapy
• 14:00 – 14:15 12 Min. 3 Min.

  • Abstract Talk
  • O 069

  Development of a VSV-based therapeutic HPV16 vaccine

  • Lydia Riepler (Innsbruck / AT)

   Vaccines, Viral vectors and gene therapy
• 14:15 – 14:30 12 Min. 3 Min.

  • Abstract Talk
  • O 070

  Harnessing mucosal immunity against respiratory viruses using adenoviral vectors expressing chemokines/cytokines as adjuvants

  • Ana Isabel Vieira Antao (Erlangen / DE)

   Viral vectors and gene therapy
• 14:30 – 14:45 12 Min. 3 Min.

  • Abstract Talk
  • O 071

  Molecular cloning of three cytomegaloviruses from Mastomys natalensis to serve as vaccine vectors against Lassa virus

  • Laura Staliunaite (Hamburg / DE)

   Viral vectors and gene therapy
• 14:45 – 15:00 12 Min. 3 Min.

  • Abstract Talk
  • O 072

  Long-lasting antibody delivery by a myotropic Adeno-Associated Virus (AAV) capsid variant – high serum levels, favourable glycosylation profile and protection from SARS-CoV-2 challenge

  • Jannik T. Wagner (Erlangen / DE)

   SARS-CoV-2, Viral vectors and gene therapy